Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The U.S. government and HIV drugmaker Gilead Sciences continue to fight over patents for Truvada and Descovy as PrEP.
PrEPception, breast feeding and HIV trial participation are front and center in updated federal guidelines.
Researchers found that Truvada as pre-exposure prophylaxis greatly reduced HIV cases in both people on PrEP and those not on it.
“All insurers failing to offer PrEP without cost sharing beginning in January 2021 are clearly not following the law.”
A new PrEP telehealth system at Stanford Children’s Health offers HIV prevention to youth and adults 25 and younger.
At a recent conference, a leading infectious disease provider in New York City advocated this as a means of improving patient satisfaction.
The first generic Truvada is now available in the United States.
The company also has plans to study monthly islatravir’s efficacy as HIV prevention among men who have sex with men.
Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.
A qualitative study of Black women at risk for HIV in Milwaukee found that low perceived risk and medical mistrust were major barriers.
This may reflect loss of the weight-suppressing effect of the older version of the drug.
ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.
Researchers studied people taking Truvada as PrEP and plan to conduct similar research on newer antiretrovirals.
Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.
Studies of the link between tenofovir use and coronavirus infection or COVID-19 outcomes have yielded mixed results.
Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.